AFT Pharmaceuticals Ltd. (AU:AFP) has released an update.
AFT Pharmaceuticals reports a record-breaking financial year with a 25% increase in operating revenue reaching $195.4 million, driven by robust sales growth in Australasia and international markets. The company’s success is highlighted by a 46% surge in net profit after tax to $15.6 million and the reduction of net debt, alongside strategic expansions and new product launches, including Maxigesic IV in the US. With strong performance and ongoing investments, AFT looks forward to a confident future in the pharmaceutical industry.
For further insights into AU:AFP stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
